Novo Files Patent-Infringement Suits to Block Ozempic Copies (1)

Novo Nordisk AS sued six generic-drug makers in Delaware federal court alleging that their proposed cheaper versions of Ozempic infringe as many as 20 patents for the blockbuster diabetes treatment, whose U.S. sales accounted for 16.5% of Novo’s 2021 revenue.

Novo filed the complaints late Friday in the U.S. District Court for the District of Delaware against EMS SA’s Rio Biopharmaceuticals, Aurobindo Pharma Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Alvogen Inc., and Zydus Lifesciences Ltd. Novo is seeking orders blocking the copycats until the latest of the patents’ expirations.

Aurobindo faces allegations ...